Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyemia treating medicine composition

A composition and drug technology, applied in the pharmaceutical composition containing them, and the application field in the preparation of drugs for the treatment and/or prevention of sepsis, can solve the problems of lack of treatment and/or preventive means for sepsis, and achieve outstanding results The effect of the treatment effect

Inactive Publication Date: 2007-08-22
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Contemporary medicine still lacks powerful treatment and / or prevention methods for sepsis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 prepares ulinastatin dry powder injection

[0033] Take 100 million units of filter-sterilized ulinastatin aqueous solution, add 20 grams of mannitol to dissolve, adjust the pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity, filter aseptically, and pack 1000 cillin bottle, freeze-dried under sterile conditions, that is.

Embodiment 2

[0034] Example 2 Preparation of α1 Thymosin Injection

[0035] Take 1.6g of α1 thymosin peptide, 10.0g of mannitol, 10.0g of glycine, add 800ml of water for injection, adjust the pH to 6.5 with sodium dihydrogen phosphate buffer solution, add water for injection to 1000ml, sterilize and filter, and pack into 1000 pencillins In the bottle, each bottle is divided into 1.0ml, and it is obtained after stoppering, corking, capping, and capping.

Embodiment 3

[0036] Example 3 Therapeutic Experiment of Ulinastatin and / or α1 Thymosin on Rats with Sepsis

[0037]Animals and groups: 128 Wister rats, weighing 240g-260g, half male and half male. UTI and α1 thymosin were used as anti-inflammatory and immunostimulatory agents respectively, and the animals were randomly divided into four groups (32 rats in each group):

[0038] ①Model group: After successful modeling, they were fed normally, and treated with the same amount of normal saline, abdominal subcutaneous and α1 thymosin through tail vein injection as in the UTI treatment group at 6 hours, 24 hours, 48 ​​hours, and 72 hours after modeling respectively. The same amount of normal saline was used as control.

[0039] ② UTI treatment group: After successful modeling, they were fed normally, and treated with 0.4ml (20,000 units) of UTI and 0.2ml of normal saline subcutaneously through the tail vein at the same time as the control group.

[0040] ③ α1 thymosin treatment group: After su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the application of ulinastatin and / or alpha-1 thymulin in preparing medicine for preventing and treating pyemia and the medicine therewith. Ulinastatin and / or alpha-1 thymulin have obvious pyemia treating effect. The medicine is prepared into injection or freeze dried powder for injection.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a new medical application of ulinastatin, α1 thymosin or a combination of both, that is, the use of ulinastatin, α1 thymosin or a combination of both in the preparation of a drug for treating and / or preventing sepsis applications, and pharmaceutical compositions containing them. Background technique [0002] Ulinastatin, also known as Human Urinary Trypsin Inhibitor (UTI; Urinastatin; or Ulinastatin), is a trypsin inhibitor isolated and purified from human urine, consisting of 143 amino acids A glycoprotein with alanine at the N-terminus, leucine at the C-terminus, and sugar chains at the 10th serine and 45th aspartic acid. Ulinastatin has a molecular weight of 40-50KD and is a heat-stable acidic protein. [0003] Ulinastatin has effective inhibitory effect on various hydrolytic enzymes, and has obvious stabilizing effect on cell membran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/57A61K9/19A61K9/08A61K47/34A61K47/26A61K47/16A61P31/00A61K38/22A61K47/10
Inventor 傅和亮侯永敏吴蓉蓉王晓岩徐娟
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com